The CEO of MedImmune, the biotech shop gobbled up last year by AstraZeneca, is quitting, the WSJ reports this afternoon.
David Mott (pictured) decided to leave because he thought it was “time for a change,” not because of any conflicts with AstraZeneca management, a company spokesman told the Journal.
Of course, the fact that Mott is apparently [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment